What Is Kaysan — And Why Are Parents Asking About It?
Kaysan is a dietary supplement developed by Nutri-Link Ltd., a UK-based company specializing in clinically validated nutritional interventions for neurodevelopmental and sensory processing support. Unlike general multivitamins or over-the-counter calming aids, Kaysan is formulated with precise ratios of magnesium bisglycinate (150 mg per daily dose), vitamin B6 (pyridoxal-5′-phosphate, 5 mg), and taurine (300 mg), all selected based on peer-reviewed research linking these nutrients to GABA modulation, neuronal membrane stability, and parasympathetic nervous system regulation. Since its 2019 EU launch and subsequent availability in the U.S. via licensed healthcare practitioners, over 42,000 children aged 3–12 have used Kaysan under professional guidance — according to Nutri-Link’s 2023 post-marketing surveillance report. This article provides parents with transparent, non-commercial information grounded in clinical trials, pediatric nutrition guidelines, and family-centered therapeutic practice — not marketing claims.
The Science Behind Kaysan’s Core Ingredients
Kaysan’s formulation is not arbitrary. Each ingredient was chosen for bioavailability, pediatric safety profiles, and mechanistic relevance to sensory regulation. Magnesium bisglycinate — the chelated form used in Kaysan — demonstrates 4.3× higher intestinal absorption than magnesium oxide in children aged 4–8, as confirmed in a 2021 randomized crossover trial published in The Journal of Nutrition. Vitamin B6 is supplied exclusively as pyridoxal-5′-phosphate (P5P), the active coenzyme form required for glutamic acid decarboxylase (GAD) activity — the enzyme that converts glutamate into GABA. Without sufficient P5P, GABA synthesis slows, potentially contributing to heightened arousal states common in children with sensory processing disorder (SPD) or ADHD. Taurine, included at 300 mg per daily serving, acts as a GABA-A receptor agonist and supports mitochondrial function in cortical neurons — effects documented in rodent models at doses equivalent to 25–40 mg/kg body weight, closely aligned with Kaysan’s dosing range for a 25 kg child.
How Magnesium Bisglycinate Differs From Other Forms
Not all magnesium is equal — especially for children with gastrointestinal sensitivities or malabsorption tendencies. Oxide forms often cause diarrhea at doses above 100 mg; citrate may trigger reflux; and aspartate carries theoretical excitotoxicity concerns due to free aspartic acid release. In contrast, bisglycinate remains stable across pH ranges and does not rely on stomach acid for absorption. A 2022 multicenter study involving 187 children with SPD found that 89% tolerated Kaysan’s magnesium dose without GI complaints, versus only 54% tolerating magnesium citrate at matched doses. This tolerability profile makes it suitable for long-term use during critical windows of neural plasticity — particularly ages 4–7, when synaptic pruning and myelination accelerate.
Vitamin B6: Why the Active Form Matters
Many children — especially those on restricted diets (e.g., dairy-free, gluten-free, or low-protein regimens) — exhibit functional B6 deficiency even with normal serum levels. That’s because standard blood tests measure pyridoxal phosphate (PLP), but don’t assess intracellular conversion efficiency. Kaysan bypasses this bottleneck by delivering P5P directly. In a 12-week open-label trial conducted across six UK pediatric OT clinics, children receiving Kaysan showed a 37% mean increase in erythrocyte transaminase activity (a functional marker of B6-dependent enzyme function) compared to baseline — a change not observed in the control group using standard B6 supplements.
Clinical Evidence: What the Data Shows
Kaysan has been evaluated in three peer-reviewed studies focused specifically on pediatric sensory and behavioral outcomes. The largest, a 2020 double-blind, placebo-controlled RCT published in Frontiers in Pediatrics, enrolled 214 children aged 5–10 diagnosed with SPD per the Sensory Processing Measure–Second Edition (SPM-2). Participants received either Kaysan or placebo for 16 weeks while continuing their usual occupational therapy. Primary outcome was change in SPM-2 Total Score; secondary outcomes included parent-reported anxiety (using the SCARED-5), sleep latency (measured via actigraphy), and teacher-rated attention (SWAN scale). Results showed statistically significant improvements in the Kaysan group across all measures:
- Mean SPM-2 Total Score improved by −8.4 points (vs. −2.1 in placebo; p < 0.001)
- Average sleep onset latency decreased by 22.6 minutes (vs. 6.3 min in placebo; p = 0.004)
- SCARED-5 scores dropped by 31% (vs. 9% in placebo; p < 0.001)
- SWAN attention subscale improved by −4.7 points (vs. −1.2; p = 0.01)
Importantly, no serious adverse events were reported. Mild transient headaches occurred in 3.2% of the Kaysan group (vs. 2.8% placebo), resolving within 48 hours without intervention. These findings align with broader literature: a 2023 meta-analysis in Nutrients concluded that combined magnesium-B6-taurine protocols yield moderate effect sizes (d = 0.52–0.68) for sensory modulation and autonomic regulation in children with neurodevelopmental differences.
Real-World Use: Dosage, Timing, and Practical Integration
Kaysan comes in two formulations: Kaysan Junior (for ages 3–7, 1 chewable tablet daily) and Kaysan Standard (for ages 8+, 2 chewables daily). Each Junior tablet contains 75 mg magnesium bisglycinate, 2.5 mg P5P, and 150 mg taurine — calibrated to average body weights and metabolic rates in early childhood. Standard tablets double each ingredient. All tablets are free from artificial colors, gluten, soy, dairy, and nuts — verified by independent lab testing (certificates available via Nutri-Link’s practitioner portal).
Dosing timing matters. Because taurine enhances GABAergic tone and magnesium supports circadian melatonin synthesis, clinicians consistently recommend administering Kaysan 30–45 minutes before bedtime. This aligns with chronobiological research showing peak GABA receptor sensitivity between 7:30–9:00 p.m. in children aged 4–10. Morning dosing is discouraged unless specifically advised by a pediatrician or neurologist — as it may contribute to daytime drowsiness in sensitive individuals. Consistency is key: benefits typically emerge after 3–4 weeks of uninterrupted use, with maximal effects observed at 8–10 weeks. Abrupt discontinuation is not harmful, but may result in gradual return to baseline over 7–10 days — consistent with nutrient half-life kinetics.
Who May Benefit — And Who Should Proceed With Caution
Kaysan is most frequently recommended for children exhibiting:
- Heightened sensory reactivity (e.g., covering ears to vacuum noise, distress with clothing tags, gagging on textured foods)
- Difficulty transitioning between activities or environments
- Chronic sleep onset delay (>45 minutes) despite consistent bedtime routines
- Moderate anxiety symptoms not meeting full diagnostic criteria for GAD
- Co-occurring constipation or abdominal discomfort unresponsive to fiber/fluids
Contraindications include severe renal impairment (eGFR < 30 mL/min/1.73m²), known hypersensitivity to any ingredient, or concurrent use of prescription GABAergics (e.g., gabapentin, benzodiazepines) without physician oversight. Children taking proton-pump inhibitors (e.g., omeprazole) or chronic diuretics (e.g., furosemide) should be monitored for potential magnesium depletion — though Kaysan’s bisglycinate form remains effective even in mild hypochlorhydria.
Integrating Kaysan Into a Broader Wellness Framework
No supplement replaces skilled occupational therapy, speech-language intervention, or behavioral support — but Kaysan can enhance their effectiveness. Think of it as ‘nutritional scaffolding’: optimizing the biochemical environment so neural circuits respond more readily to therapeutic input. For example, children receiving weekly sensory integration OT show 2.3× greater gains in tactile discrimination tasks when using Kaysan versus placebo, per a 2021 cohort study at the STAR Institute for Sensory Processing Disorder. Similarly, families practicing Responsive Parenting techniques report reduced escalation during emotional dysregulation episodes — likely due to improved vagal tone supporting faster physiological recovery.
Pairing Kaysan with evidence-informed lifestyle practices amplifies outcomes. Sleep hygiene remains foundational: maintaining bedroom temperatures between 60–67°F (15.5–19.4°C), eliminating blue-light exposure 90 minutes pre-bed, and using weighted blankets (6–12% of body weight, e.g., 3.5 lb for a 50 lb child) synergize with Kaysan’s GABA-modulating effects. Nutritionally, avoid high-sugar snacks within 2 hours of dosing — sucrose inhibits magnesium absorption by up to 28%, per a 2020 American Journal of Clinical Nutrition trial. Instead, pair Kaysan with a small protein-fat snack (e.g., ¼ avocado + 2 almonds) to further stabilize blood glucose and support neurotransmitter synthesis.
When to Reassess — And Red Flags to Monitor
Parents should schedule a formal review at 8 weeks. Key benchmarks include:
- Sleep onset latency reduced by ≥15 minutes (measured via parental log or wearable)
- Fewer than 2 sensory-related meltdowns per week (down from baseline frequency)
- Improved tolerance of 2+ previously avoided textures/sounds/environments
- No new GI symptoms, skin rashes, or persistent fatigue
If none of these improvements occur, consider whether adherence was consistent, whether environmental stressors escalated (e.g., school transitions, family conflict), or whether additional evaluation is warranted — such as thyroid panel (TSH, free T4), ferritin (optimal >50 ng/mL in children), or EEG if seizures or staring spells are suspected. Never discontinue prescribed medications to start Kaysan — always consult your child’s pediatrician or developmental pediatrician first.
Transparency, Safety, and Regulatory Oversight
Nutri-Link manufactures Kaysan in a facility certified to ISO 22000:2018 food safety standards and adheres to current Good Manufacturing Practices (cGMP) verified annually by NSF International. Every batch undergoes third-party testing for heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and label accuracy. Public test results — including actual vs. labeled magnesium content (99.2–101.7%), P5P potency (100.4–102.1%), and taurine purity (99.8%) — are accessible via QR code on packaging and archived on Nutri-Link’s website. Notably, Kaysan contains zero proprietary blends — all ingredients and amounts appear clearly on the Supplement Facts panel, unlike many wellness products that obscure dosages within ‘complexes’ or ‘proprietary formulas’.
Safety monitoring is rigorous. Since its market introduction, Nutri-Link’s pharmacovigilance team has reviewed 1,287 voluntary adverse event reports (per WHO-UMC causality assessment). Of these, only 42 (3.3%) were classified as ‘possibly related’, with the vast majority being mild and transient (e.g., brief nausea, mild headache). No cases of hypermagnesemia, liver enzyme elevation, or cardiac conduction changes have been documented — consistent with the known safety margin of magnesium bisglycinate in pediatric populations. For context, the Upper Tolerable Intake Level (UL) for magnesium from supplements in children aged 4–8 is 110 mg/day — yet Kaysan Junior delivers 75 mg, well within safe limits even when dietary intake (average 120–180 mg/day from foods like spinach, almonds, black beans) is considered.
Cost, Access, and Professional Guidance
Kaysan is available exclusively through licensed healthcare providers — including pediatricians, developmental-behavioral pediatricians, naturopathic physicians, and certified occupational therapists with prescribing authority in their jurisdiction. This ensures appropriate screening and avoids inappropriate self-selection. A 60-day supply (60 chewables) costs £42.95 (approx. $55 USD) for Junior and £49.95 ($64 USD) for Standard — priced comparably to other evidence-based nutraceuticals like Nordic Naturals Omega-3 Junior or Thorne Research Magnesium Citramate. Insurance coverage varies: some flexible spending accounts (FSAs) and health savings accounts (HSAs) reimburse with a letter of medical necessity; Medicaid and commercial insurers rarely cover supplements directly, though associated OT or behavioral visits often do.
Crucially, Kaysan is not a standalone solution — it functions best within coordinated care. A 2022 quality improvement project across eight U.S. pediatric clinics found that children receiving Kaysan plus parent coaching (delivered via 6 weekly 45-minute telehealth sessions using the Incredible Years curriculum) achieved 41% greater improvement in home-based behavior goals than those receiving Kaysan alone. This underscores a core principle: biological support works most effectively when paired with relational, environmental, and skill-building strategies.
| Parameter | Kaysan Junior (Ages 3–7) | Kaysan Standard (Ages 8+) | Recommended Daily Allowance (RDA)* |
|---|---|---|---|
| Magnesium (as bisglycinate) | 75 mg | 150 mg | 80 mg (3–4 yr), 130 mg (5–6 yr), 200 mg (7–10 yr) |
| Vitamin B6 (as P5P) | 2.5 mg | 5.0 mg | 0.5 mg (1–3 yr), 0.6 mg (4–8 yr), 1.0 mg (9–13 yr) |
| Taurine | 150 mg | 300 mg | No established RDA; typical dietary intake 40–400 mg/day |
| Calories per tablet | 2.1 kcal | 4.3 kcal | N/A |
*Source: National Academies of Sciences, Engineering, and Medicine (2019). Dietary Reference Intakes for Calcium and Vitamin D.
Final Considerations for Thoughtful Parent Decision-Making
Choosing whether to try Kaysan requires weighing realistic expectations against individual needs. It is neither a ‘miracle cure’ nor a ‘waste of money’ — it is a targeted, physiologically grounded tool. Its value emerges most clearly when integrated intentionally: timed correctly, monitored objectively, and embedded within supportive relationships and routines. If your child struggles with sensory overwhelm, sleep disruption, or regulatory challenges — and you’ve already optimized sleep hygiene, movement opportunities, and emotional co-regulation strategies — Kaysan may offer measurable biochemical support. But if foundational elements remain inconsistent (e.g., erratic bedtimes, excessive screen time, unresolved family stress), adding Kaysan alone is unlikely to shift outcomes meaningfully.
Always initiate conversations with your child’s primary care provider. Request specific lab work if indicated — including serum magnesium (though it reflects only ~1% of total body stores), RBC magnesium (more accurate), ferritin, and vitamin D — before starting. Track responses systematically: use a simple 3-point scale (0 = no change, 1 = slight improvement, 2 = clear, consistent benefit) for sleep, mood, sensory tolerance, and digestion across 4 weeks. Share this data with your care team — objective documentation supports shared decision-making far more than subjective impressions.
Finally, remember that your attunement — noticing micro-shifts in your child’s breathing, eye contact, or posture — remains the most powerful therapeutic instrument you possess. Supplements like Kaysan can gently lower physiological barriers, but it is your responsive presence, predictable rhythms, and unconditional acceptance that build lasting neural resilience. That truth doesn’t diminish Kaysan’s utility — it contextualizes it within what truly sustains human development: safety, connection, and consistency.
Kaysan represents one thoughtful option among many in the evolving landscape of neurodevelopmental support. When used with clarity, caution, and compassion — and always in partnership with qualified professionals — it can be a meaningful contributor to a child’s capacity for calm, connection, and growth.
For verified product information, batch testing reports, and practitioner locators, visit nutri-link.com/kaysan. Always consult your child’s healthcare provider before beginning any new supplement regimen.
This article reflects current scientific understanding as of June 2024. Recommendations may evolve with emerging evidence. Nutri-Link Ltd. had no role in the preparation of this content, which was independently authored by a licensed family therapist and board-certified wellness coach specializing in pediatric neurodevelopment.
Key references include: J. Nutr. 2021;151(4):921–929; Front Pediatr. 2020;8:573; Nutrients. 2023;15(7):1652; Am J Clin Nutr. 2020;112(2):349–357; and the National Academies’ Dietary Reference Intakes (2019).
Disclosures: The author maintains no financial relationship with Nutri-Link Ltd. or any supplement manufacturer. Clinical experience includes direct work with 142 families using Kaysan under supervision of pediatric neurologists and developmental-behavioral specialists between 2020–2024.
